MarketPeel
Insider Trading Intelligence
KT

Karen L. Tubridy

AKBA
SVP, CHIEF DEVELOPMENT OFFICER · AKEBIA THERAPEUTICS, INC. · CIK 0001589888
FILING MIX · LIFETIME67%/33%
BUYS
2
SELLS
1
TOTAL VALUE
$30.0K
COMPANIES
1
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
84,679
AVG SELL PX
$8.70
TRADE KIND
SHOWING 3 / 3
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons
Forward-return performance of every backtestable P/S trade by Karen L. Tubridy, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+0.00%+2.14%+0.41%+1.74%+1.74%
14d1+100.00%-33.71%-9.10%-24.61%-24.61%
30d1+100.00%-10.26%-11.16%+0.90%+0.90%
60d1+100.00%-9.36%-2.99%-6.37%-6.37%
90d1+0.00%+29.76%+2.86%+26.90%+26.90%
180d1+0.00%+14.32%+18.52%-4.21%-4.21%
1y1+100.00%-60.99%+30.79%-91.78%-91.78%
2y1+100.00%-75.65%+52.14%-127.79%-127.79%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
AKBA · 84,679 shares · as of Feb 28, 2020
022,03344,06766,10088,133SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
FLOW · 2 buys / 1 sellsCOVERAGE · 1 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILED
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
30,00088,133Feb 28, 2020Mar 2, 2020
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
85,00085,000Feb 28, 2020Mar 2, 2020
AKBA
AKEBIA THERAPEUTICS, INC.
SALE
SVP, Chief Development Officer
3,454$8.70$30.0K84,679Feb 28, 2020Mar 2, 2020
Other insiders · AKBA
Loading peer insiders…
About this filer
CIK 0001589888
ROLE
SVP, Chief Development Officer
PRIMARY
AKBA
COMPANIES
1
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001589888DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback